Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeoVax Labs, Inc.GOVX · Entity 8419 | VP, Business Development | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeoVax Labs, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-06-17 | Direct | 17,600 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 17,600 · Balance 17,600 F1: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:19 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 17,600 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021316 · rdgdoc.xml · derivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2036-06-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:39 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 70,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019628 · rdgdoc.xml · derivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-01-02 F2 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| April 10, 2025 Filed Apr 10, 2025 20:01 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | PurchaseCommon Stock | 6,000 | $0.99 | $5,940.00 |
DisclosureSEC source: 0001437749-25-011658 · rdgdoc.xml · nonDerivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,191 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:09 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 15,700 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026800 · rdgdoc.xml · derivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-08-12 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. Read SEC document |
| August 01, 2023 Filed Aug 14, 2023 20:49 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001437749-23-023736 · rdgdoc.xml · derivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-12-07 F1 · date: This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F2 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 19:10 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | PurchaseCommon Stock | 1,000 | $0.82 | $820.00 |
DisclosureSEC source: 0001437749-22-016567 · rdgdoc.xml · nonDerivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,860 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.